Biotechnology RETA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Reata Pharmaceuticals, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm October 16, 2020
Biotechnology REATA PHARMACEUTICALS, INC. CLASS ACTION LAWSUIT – Reata Investors Who Have Suffered Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C. October 16, 2020
Biotechnology Pomerantz Law Firm Announces the Filing of a Class Action against Reata Pharmaceuticals, Inc. and Certain Officers – RETA October 15, 2020
Biotechnology BIOMARIN CLASS ACTION UPDATE BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & FotI, LLC Reminds Investors of Lead Plaintiff Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN October 15, 2020
Biotechnology ROSEN, A TOP RANKED LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – BMRN October 15, 2020
Biotechnology VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention (PCI) in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at Transcatheter Cardiovascular Therapeutics (TCT) Connect 2020 October 15, 2020
Biotechnology Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients October 15, 2020
Biotechnology IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm October 15, 2020
biotech stock market
Search
Search
biotech stock market